These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17089053)

  • 1. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
    Takano M; Kikuchi Y; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Sugiyama T
    Oncol Rep; 2006 Dec; 16(6):1301-6. PubMed ID: 17089053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
    Takano M; Sugiyama T; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Kikuchi Y
    Int J Clin Oncol; 2007 Aug; 12(4):256-60. PubMed ID: 17701003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy.
    Kunito S; Takakura S; Nagata C; Saito M; Yanaihara N; Yamada K; Okamoto A; Sasaki H; Ochiai K; Tanaka T
    J Obstet Gynaecol Res; 2012 Dec; 38(12):1367-75. PubMed ID: 22639843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.
    Nishino K; Aoki Y; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
    Gynecol Oncol; 2005 Jun; 97(3):893-7. PubMed ID: 15894369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
    Takada T; Iwase H; Iitsuka C; Nomura H; Sakamoto K; Omatsu K; Takeshima N; Takizawa K
    Int J Gynecol Cancer; 2012 May; 22(4):573-8. PubMed ID: 22398705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
    Sugiyama T; Okamoto A; Enomoto T; Hamano T; Aotani E; Terao Y; Suzuki N; Mikami M; Yaegashi N; Kato K; Yoshikawa H; Yokoyama Y; Tanabe H; Nishino K; Nomura H; Kim JW; Kim BG; Pignata S; Alexandre J; Green J; Isonishi S; Terauchi F; Fujiwara K; Aoki D
    J Clin Oncol; 2016 Aug; 34(24):2881-7. PubMed ID: 27400948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
    Takano M; Sugiyama T; Yaegashi N; Sagae S; Kuzuya K; Udagawa Y; Tsuda H; Suzuki M; Kigawa J; Goto T; Tsuda H; Moriya T; Kikuchi Y
    Int J Gynecol Cancer; 2010 Dec; 20(9):1506-10. PubMed ID: 21119366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival impact of adjuvant paclitaxel and carboplatin for early-stage ovarian clear-cell carcinoma with complete surgical staging.
    Kajiyama H; Shibata K; Suzuki S; Ino K; Kawai M; Nagasaka T; Nawa A; Kikkawa F
    Gynecol Obstet Invest; 2011; 72(4):252-6. PubMed ID: 22041903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
    Takakura S; Takano M; Takahashi F; Saito T; Aoki D; Inaba N; Noda K; Sugiyama T; Ochiai K;
    Int J Gynecol Cancer; 2010 Feb; 20(2):240-7. PubMed ID: 20169667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma.
    Takakura S; Saito M; Ueda K; Motegi M; Takao M; Yamada K; Okamoto A; Niimi S; Sasaki H; Tanaka T; Ochiai K
    Int Surg; 2007; 92(4):202-8. PubMed ID: 18050828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
    Ma SK; Zhang HT; Wu LY; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):784-8. PubMed ID: 18396695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience.
    Chun KC; Kim JJ; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
    Gynecol Obstet Invest; 2011; 72(3):208-14. PubMed ID: 21968161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.
    Suzuki K; Takakura S; Saito M; Morikawa A; Suzuki J; Takahashi K; Nagata C; Yanaihara N; Tanabe H; Okamoto A
    Int J Gynecol Cancer; 2014 Sep; 24(7):1181-9. PubMed ID: 25010038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.
    Kita T; Kikuchi Y; Kudoh K; Takano M; Goto T; Hirata J; Tode T; Nagata I
    Oncol Rep; 2000; 7(2):327-31. PubMed ID: 10671681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
    Bamias A; Psaltopoulou T; Sotiropoulou M; Haidopoulos D; Lianos E; Bournakis E; Papadimitriou C; Rodolakis A; Vlahos G; Dimopoulos MA
    Cancer; 2010 Mar; 116(6):1462-8. PubMed ID: 20108307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful optimal debulking surgery following chemotherapy combined with irinotecan hydrochloride and cisplatin for advanced clear cell carcinoma of the ovary].
    Hirakawa H; Futagami M; Yokoyama Y; Hakamada K; Mizunuma H
    Gan To Kagaku Ryoho; 2011 May; 38(5):857-60. PubMed ID: 21566454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.